Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Health Aff (Millwood) ; 43(1): 36-45, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-38190604

RESUMO

Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs and access in the coming years. In a sample of 58,529 people with a new insurer-approved PrEP prescription, we estimated risk-adjusted percentages of patients who abandoned (did not fill) their initial prescription across six out-of-pocket cost categories. We then simulated the percentage of patients who would abandon PrEP under hypothetical changes to out-of-pocket costs, ranging from $0 to more than $500. PrEP abandonment rates of 5.5 percent at $0 rose to 42.6 percent at more than $500; even a small increase from $0 to $10 doubled the rate of abandonment. Conversely, abandonment rates that were 48.0 percent with out-of-pocket costs of more than $500 dropped to 7.3 percent when those costs were cut to $0. HIV diagnoses were two to three times higher among patients who abandoned PrEP prescriptions than among those who filled them. These results imply that recent legal challenges to the provision of PrEP with no cost sharing could substantially increase PrEP abandonment and HIV rates, upending progress on the HIV/AIDS epidemic.


Assuntos
Síndrome da Imunodeficiência Adquirida , Epidemias , Profilaxia Pré-Exposição , Humanos , Gastos em Saúde , Custo Compartilhado de Seguro
2.
Health Aff (Millwood) ; 28(4): 1103-13, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19597210

RESUMO

Brazil has one of the developing world's largest, and arguably most successful, AIDS treatment programs. In this paper we review the treatment program, including controversial policies that Brazil has used to promote widespread local and global access to AIDS treatment. We also examine the lessons learned from this program and highlight the challenges Brazil faces, including the rising costs of AIDS treatment and changes in donors' funding priorities. Finally, we explore the relevance of Brazil's treatment program for other countries and its broad implications for global AIDS and health policy.


Assuntos
Síndrome da Imunodeficiência Adquirida/terapia , Acessibilidade aos Serviços de Saúde/normas , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Antirretrovirais/economia , Antirretrovirais/provisão & distribuição , Antirretrovirais/uso terapêutico , Brasil , Custos de Medicamentos , Educação em Saúde , Política de Saúde , Acessibilidade aos Serviços de Saúde/economia , Humanos , Avaliação de Programas e Projetos de Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA